Navigation Links
PharmAthene Reports First Quarter 2012 Financial Results
Date:5/8/2012

ive agent of smallpox, and related products, once SIGA receives the first $40 million in net profits from sales of ST-246.  For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, challenges related to the implementation of our NYSE Amex compliance plan as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
2. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
3. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
4. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
5. PharmAthene Reports Third Quarter 2011 Financial and Operating Results
6. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
7. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
8. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
9. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
10. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
11. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013   NineSigma , Inc., of ... its launch, NineSights.com is now the innovation ... the worldwide community of innovators. From technology ... experts, NineSights stands out for its large community of ... technical disciplines, all vetted by NineSigma. The community is ...
(Date:6/19/2013)... , June 19, 2013 Biotechnology industry pioneer ... up with financial software provider BlackLine Systems  and ... SAP ) for a webinar next week entitled ... Solutions from BlackLine and SAP to Help Keep Its Account ... http://photos.prnewswire.com/prnh/20061117/LAF027LOGO ) The webinar, geared at ...
(Date:6/19/2013)... Canada (PRWEB) June 19, 2013 ... trial business can potentially be worth up to ... this opportunity, the Indian government is taking serious ... trials the process. , This presentation will examine:, ... trial regulations ,     Immediate and long term ...
(Date:6/19/2013)... Blue Earth, MN (PRWEB) June 19, 2013 ... drugs of abuse tests, today announced that it has ... Canada to market and sell its DrugCheck® NxStep ... licensure allows use of the rapid screening device in ... NxStep Onsite Drug Screen Cup received Health Canada Class ...
Breaking Biology Technology:NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 2Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 4Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
... first time, researchers have developed a 3D picture of ... of the human cellular machinery, enhancing our understanding of ... opening up new possibilities for stepping in to prevent ... many tactical manoeuvres employed by the virus. The ...
... (Nasdaq: BIOD ) today announced that Dr. ... present a corporate update at the 29th Annual JPMorgan ... a.m. Pacific Time (12:30 p.m. Eastern Time). The update ... formulations of its lead product, Linjeta™, including milestones and ...
... Biosciences, Inc. (Nasdaq: RDEA ) today announced ... of RDEA594 in combination with the current standard of ... accounts for greater than 90% of the unit sales ... only 30-40% of gout patients respond adequately to allopurinol ...
Cached Biology Technology:Researchers visualize herpes virus' tactical maneuver 2Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 2Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 3Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 4Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 5Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 6Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 7
(Date:6/18/2013)... Scientists at the University of Calgary,s Faculty of Medicine ... the body from harmful bacteria. Platelets, a component of ... search for specific bacteria, and upon detection, seal it ... which were published in Nature Immunology this ... of immunity. , "The science community has known that ...
(Date:6/18/2013)... At Brandeis University, sophisticated computational models and advances ... the complex interplay between genomic data, virus structure ... critical for replication. , "We ... will help researchers alter virus assembly, leaving viruses ... first author of the scientific paper describing the ...
(Date:6/18/2013)... The National Institutes of Health has awarded $12.7 ... a selection of pharmaceutical industry compounds to explore ... including Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. ... Uses for Existing Molecules, is led by the ... funded by the NIH Common Fund. , The ...
Breaking Biology News(10 mins):Immunity mechanism discovered 2Computer modeling technique goes viral at Brandeis 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4
... 4, 2010 -- Supercomputer simulations at the Department of Energy,s ... acids could have contributed to the origins of life. ... directs ORNL,s Center for Molecular Biophysics and holds a Governor,s ... probe an organic chemical reaction that may have been important ...
... USA (October 4, 2010) The Aeras Global TB ... grant from the United States Food and Drug Administration ... TB vaccine development. The FDA grant, which supports the ... United States, the United Kingdom and South Africa, will ...
... Major, PhD, assistant professor of cell and developmental biology, ... Health Director,s New Innovator Awards, one of the NIH,s ... fund his work to address a significant medical science ... contribute to specific cellular and disease processes such as ...
Cached Biology News:Powerful supercomputer peers into the origin of life 2Aeras-led research consortium receives FDA support 2UNC scientist receives NIH director's New Innovator Award 2
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
Bovine Pulmonary Artery Endothelial Cells (BPAEC) (>500,000 cells)...
Bovine Aortic Smooth Muscle Cells (BAOSMC) (>500,000 cells)...
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
Biology Products: